The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Insight into the Downregulation of NK Cells in SLE Patients

Insight into the Downregulation of NK Cells in SLE Patients

June 4, 2018 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Studies of T cells from patients with systemic lupus erythematosus (SLE) have shown the downregulated expression of the CD3ζ chain, as well as the increased production of IFN-ɣ. Moreover, research has revealed that FcԑRIɣ replaces CD3ζ in these T cells, resulting in hyperactivated T cells with a proinflammatory phenotype. Researchers have suggested the downregulation of CD3ζ may be the result of genetic polymorphisms, epigenetic changes, altered transcription and/or increased degradation.

You Might Also Like
  • Characterization of Autoreactive B Cells in Patients with SLE & RA
  • Insight into Endothelial Dysfunction in Early SLE Patients without Cardiovascular Disease
  • Gene Expression Markers in T Cells Help Identify SLE Patient Subtypes
Also By This Author
  • New Methodology to Improve Cartilage Repair

Attention has turned to the role of CD3ζ in the natural killer (NK) cells of SLE patients. New research has revealed that downregulation of CD3ζ also appears to confer a proinflammatory phenotype to SLE NK cells. Abel Suarez-Fueyo, PhD, a research scientist at Harvard Medical School, Boston, and colleagues propose that the downregulation of CD3ζ contributes to the previously recognized altered function of NK cells in SLE patients. The results of the study were published in the May issue of the Journal of Immunology.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“As CD3ζ is critical for proper signaling in NK cells, and NK cell dysfunction has been described in SLE patients, we have studied the relationship between CD3ζ levels in NK cells and their function,” write the authors in their discussion. “We found a direct correlation between the levels of CD3ζ and ADCC [antibody-dependent cellular cytotoxicity], a mechanism that depends on CD16, a molecule associated with CD3ζ and FcεRIg, and an inverse correlation with natural cytotoxicity.”

The researchers also note that CD16 is involved in the response to herpes simplex virus, cytomegalovirus and tumor cells. The researchers also suggest this loss of CD3ζ in SLE NK cells and the coincident decrease in CD16 function may also contribute to the increased risk of viral infections in patients with SLE.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Natural cytotoxicity from NK cells depends on several receptors, including NKp30 and NKp46, which signal via CD3ζ or the FcԑRIɣ chain. Both NKp30 and NKp46 play a significant role in natural cytotoxicity and are more dependent on FCԑRIɣ than CD3ζ. Moreover, previous research showed human NK cells deficient in FcԑRIɣ have increased ADCC, reduced natural cytotoxicity and reduced cytokine production. Thus, CD3ζ seems to be important for CD16 signaling, whereas natural cytotoxicity relies on FCԑRIɣ.

The investigators also note the downregulated expression of CD3ζ did not extend to NKT cells. “In this study, we found decreased CD3ζ levels in NK cells and T cells from SLE patients, but not in NKT type I cells,” write the authors. “This can occur as a consequence of common mechanisms affecting NK and T cells, but not NKT type I; however, additional factors can contribute to this discrepancy, including cohort bias and treatment. Nonetheless, we did not find any relation between patients’ therapy and CD3ζ levels.” In other words, the decreased levels of CD3ζ in the NK cells of SLE patients were independent of disease status or treatment.

Pages: 1 2 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: natural killer cells, SLE, systemic lupus erythematosus (SLE)

You Might Also Like:
  • Characterization of Autoreactive B Cells in Patients with SLE & RA
  • Insight into Endothelial Dysfunction in Early SLE Patients without Cardiovascular Disease
  • Gene Expression Markers in T Cells Help Identify SLE Patient Subtypes
  • Patients with Lupus: Plasmacytoid Dendritic Cells Fail to Induce Regulatory B Cells

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.